Multiple myeloma

Blood

Volumn 111, Issue 6, 2008, Pages 2962-2972

  Kyle, Robert A ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENCE JONES PROTEIN; BORTEZOMIB; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISTARAL; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; NEUROSEDYN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROTEASOME; QUININE; SERUM GLOBULIN; STEROID; THALIDOMIDE; UBIQUITIN; UNCLASSIFIED DRUG; VINCRISTINE; TUMOR MARKER;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FETUS MALFORMATION; GAMMOPATHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERGAMMAGLOBULINEMIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BLOOD; HISTORY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STEM CELL TRANSPLANTATION;

ANIMALS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STEM CELL TRANSPLANTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 42449114035     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-078022     Document Type: Review

References (101)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Rajkumar SV, Kyle RA. Plasma cell disorders. In: Goldman L, Ausiello D. eds. Cecil Textbook of Medicine, 23rd ed. Philadelphia. PA: Saunders; 2007;1426-1437.
3. Kyle RA, Therneau TM, Rajkumar SV. et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
4. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354: 1362-1369.
5. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007; 356:2582-2590.
6. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MR Melton LJ 3rd. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101:2667-2674.
7. Solly S. Remarks on the pathology of mollities ossium with cases. Med ChirTrans Lond. 1844; 27:435-461.
8. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med ChirTrans Lond. 1850; 33:211-232.
9. Kyle RA. Multiple myeloma: an odyssey of discovery. BrJ Haematol. 2000;111:1035-1044.
10. Bence Jones H. Chemical pathology. Lancet 1847;2:88-92.
11. Bence Jones H. On the new substance occurring in thein the urine of a patient with mollities ossium. Philos Trans R Soc Lond. 1848;138:55-62.
12. Waldeyer W. Ueber bindegewebszellen. Arch Microbiol Anat. 1875;11:176-194.
13. Wright JH. A case of multiple myeloma. Trans Assoc Am Phys. 1900;15:137-147.
14. Arinkin MI. Die intravitale Untersuchungsmethodik des Knochenmarks. Folia Haematol. 1929;38:233-240.
15. Rosenthal N, Vogel P. Value of the sternal puncture in the diagnosis of multiple myeloma. J Mt Sinai Hosp. 1938;4:1001-1019.
16. Geschickter CF, Copeland MM. Multiple myeloma. Arch Surg. 1928;16:807-863.
17. Heller JD. Die mikroscopisch-chemisch-pathologische untersuchung. Vienna: Braumuller and Seidel; 1846.
18. Fleischer R XXIV. Ueber das Vorkommen des sogenannten Bence Jones' schen Eiweisskorpers im normalen Knochenmark. Arch Pathol Anatom Physiol Klin Med. 1880;80:842-849.
19. Bayne-Jones S, Wilson DW. Immunological reactions of Bence-Jones proteins: II. Differences between Bence-Jones proteins from various sources. Bull Johns Hopkins Hosp. 1922;33:119-125.
20. Korngold L, Lipari R. Multiple-myeloma proteins" III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins. Cancer. 1956;9:262-272.
21. Edelman GM, Gally JA. The nature of Bence-Jones proteins: chemical similarities to polypeptide chains of myeloma globulins and normal gamma-globulins. J Exp Med. 1962;116:207-227.
22. Perlzweig WA, Delrue G, Geschicter C. Hyperproteinemia associated with multiple myelomas: report of an unusual case. JAMA. 1928;90:755-757.
23. Tiselius A. A new apparatus for electrophoretic analysis of colloidal mixtures. Trans Faraday Soc. 1937;33:524.
24. Tiselius A, Kabat EA. Electrophoretic study of immune sera and purified antibody preparation. J Exp Med. 1939;69:119-131.
25. Longsworth LG, Shedlovsky T, MacInnes DA. Electrophoretic patterns of normal and pathological human blood, serum, and plasma. J Exp Med. 1939;70:399-413.
26. Kunkel HG, Tiselius A. Electrophoresis of proteins on filter paper. J Gen Physiol. 1951;35:89-118.
27. Grabar P, Williams CA. Methode permettant l'etude conjuguee des proprietes electrophoretiques et immunochimiques d'un melange de proteines; application au serum sanguin. Biochim Biophys Acta. 1953;10:193-194.
28. Wilson AT. Direct immunoelectrophoresis. J Immunol. 1964;92:431-434.
29. Waldenström J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1961;56:211-231.
30. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64:814-826.
31. Alwall N. Urethane and stilbamidine in multiple myeloma: report on two cases. Lancet. 1947;2: 388-389.
32. Holland JR, Hosley H, Scharlau C, et al. A controlled trial of urethane treatment in multiple myeloma. Blood. 1966;27:328-342.
33. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci. 1958;68:1128-1132.
34. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep. 1962;21:87-99.
35. Hoogstraten B, Sheehe PR, Cuttner J, et al. Mel phalan in multiple myeloma. Blood. 1967;30:74-83.
36. Maas RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962;16:257-259.
37. Salmon SE, Shadduck RK, Schilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother Rep. 1967;51:179-187.
38. McIntyre OR, Pajak TF, Kyle RA, Cornwell GG 3rd, Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Med Pediatr Oncol. 1985;13:239-243.
39. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-1685.
40. Lee BJ, Sahakian G, Clarkson BD, Krakoff IH. Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer. 1974;33:533-538.
41. Case DC Jr, Lee DJ 3rd, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977;63:897-903.
42. Myeloma Trialists' Collaborative Group. Combination chemotherapy vs melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
43. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491-496.
44. Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R. Identical twin marrow transplantation in multiple myeloma. Acta Haematol. 1982;68:215-223.
45. Fefer A, Cheever MA, Greenberg PD. Identicaltwin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst. 1986;76: 1269-1273.
46. Gahrton G, Tura S, Flesch M, et al. Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation. Blood. 1987;69:1262-1264.
47. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822-824.
48. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66:55-62.
49. Barlogie B, Alexanian R, Dicke KA, et al. Highdose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869-872.
50. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. N Engl J Med. 1999;341: 1565-1571.
51. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
52. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see Comment]. N Engl J Med. 2005;352:2487-2498.
53. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050-4053.
54. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108: 3458-3464.
55. Rajkumar SV. Thalidomide: tragic past and promising future. Mayo Clin Proc. 2004;79:899-903.
56. Lenz W. Thalidomide and congenital abnormalities. Lancet. 1962;1:45.
57. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358.
58. Woodyatt PB. Thalidomide. Lancet. 1962;1:750.
59. Grabstad H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin Pharmacol Ther. 1965;6:298-302.
60. Olson KB, Hall TC, Horton J, Khung CL, Hosley HF. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther. 1965;6:292-297.
61. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
62. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21: 4444-4454.
63. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79:13-21.
64. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59: 2615-2622.
65. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998;58:4342-4348.
66. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancles. J Clin Oncol. 2002;20:4420-4427.
67. Wilk S, Orlowski M. Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J Neurochem. 1980;35: 1172-1182.
68. Wilk S, Orlowski M. Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolylprolinal, a transition state aldehyde inhibitor. J Neurochem. 1983;41:69-75.
69. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
70. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-3901.
71. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100:3063-3067.
72. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357:2123-2132.
73. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357:2133-2142.
74. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
75. Greipp PR, San Miguel JF, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
76. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and riskadapted therapy (mSMART): Consensus Statement. Mayo Clin Proc. 2007;82:323-341.
77. Attal M, Harousseau JL, StoppaAM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
78. Child JA. Morgan GJ. Davies FE. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-1883.
79. Fermand JP, Ravaud P. Chevret S. et al. Highdose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
80. Barlogie B. Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929-936.
81. Attal M, Harousseau JL. Facon T, et al. Single vs double autologous stem-cell transplantation for multiple myeloma [see comment]. N Engl J Med. 2003;349:2495-2502.
82. Blade J, Rosinol L, Sureda A. et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755-3759.
83. Bruno B. Rotta M. Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-1120.
84. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367:825-831.
85. Facon T. Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide vs melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-1218.
86. Alexanian R. Barlogie B. Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
87. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
88. Rajkumar SV, Hussein M. Catalano J. et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone vs dexamethasone alone as primary therapy for newly diagnosed multiple myeloma [abstract]. Blood. 2006; 108:795.
89. Lacy MQ, Gertz MA, Dispenzieri AA, et al. Longterm results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82:1179-1184.
90. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. Arandomized phase III trial of lenalidomide plus high-dose dexamethasone vs lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood. 2006; 108:799.
91. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776-783.
92. Harousseau J, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006; 91:1498-1505.
93. Harousseau J-L, Marit G, Caillot D, et al. VELCADE/dexamethasone (Vel/Dex) vs VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial [abstract]. Blood. 2006;108:56.
94. Hulin C, Virion J, Leleu X, et al. Comparison of melphalan-prednisone- thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial [abstract], J Clin Oncol. 2007;25:8001.
95. Mateos M-V, Hernandez J-M, Hernandez M-T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165-2172.
96. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459-4465.
97. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study. J Clin Oncol. 2007;25:2434-2441.
98. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102: 3447-3454.
99. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474-3480.
100. Attal M, Harousseau J-L, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108:3289-3294.
101. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21:529-534.